AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03349515
Drug: Provodine-Iodine Solution
RxNorm normalized name: Iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Group A will receive three drops of povidone-iodine ophthalmic solution in each eye, with the right eye to receive the drops first. The eye drops will be administered by the study anesthesiologist. After application of either solution to the eyes of the patient, any change in ventilation can be detected and timed by observation of the capnography (end-tidal carbon dioxide) and direct observation of the chest wall with use of the iPhone stopwatch feature again. The capnograph is a standard monitor of respiration used during the administration of general anesthesia. Data collected at this time will include whether or not there was a change in respiration, what this change in respiration was, if assisted ventilation was required, how long assisted ventilation was required (if applicable), HR, BP, RR, SaO2 , ETCO2, InspSevo, and ExpSevo. This study intervention and data collection will take less than 5 minutes.
Trial: NCT01776463
Drug: Z-360
RxNorm normalized name: Z-160
DrugBank: Z-160 (DB12743)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00973765
Drug: bactrim
RxNorm normalized name: Bactrim
DrugBank: Trimethoprim (DB00440)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: bactrim DS (800/160) 2 pills PO BID x 7 days
Trial: NCT01322360
Drug: Morphine Sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01190878
Drug: DuraSite Vehicle
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle dosed BID
Trial: NCT00233103
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline arm
Trial: NCT03731988
Drug: lidocaine/prilocaine (5%) application
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
Trial: NCT01014650
Drug: GLYX-13
RxNorm normalized name: Glyxambi
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: single IV or SC dose
Trial: NCT01014650
Drug: IV normal saline
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV dose of normal saline
Trial: NCT02943759
Drug: Chlorhexidine gluconate
RxNorm normalized name: Chlorhexidine Gluconate
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2%chlorhexidine gluconate , anti bacterial root canal irrigant solution
Trial: NCT01085591
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02011113
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 4 mg oral pomalidomide once daily Days 1-21 of each 28-day cycle
Trial: NCT02011113
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg or 20 mg oral dexamethasone once daily on Days 1, 8, 15, 22 of each 28-day cycle
Trial: NCT05818618
Drug: Clobetasol Topical Gel
RxNorm normalized name: clobetasol Topical Gel
DrugBank: Clobetasol (DB11750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topic Clobetasol gel applied locally on OLP lesions.
Trial: NCT02201238
Drug: Menthol
RxNorm normalized name: Menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menthol
Trial: NCT00221611
Drug: Administration of intrathecal baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02583893
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT02583893
Drug: Mitoxantrone
RxNorm normalized name: Mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02583893
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02583893
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03660293
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cardio-protective agents
Trial: NCT02401295
Drug: ATRA
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02401295
Drug: Itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03660293
Drug: Captopril
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cardio-protective agents
Trial: NCT03660293
Drug: L-carnitine
RxNorm normalized name: L-Carnitine
DrugBank: Levocarnitine (DB00583)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: cardio-protective agents
Trial: NCT03361384
Drug: Alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00653965
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00967044
Drug: Panobinostat
RxNorm normalized name: Panobinostat
DrugBank: Panobinostat (DB06603)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Starting dose of 10 mg by mouth per day, self-administered (by patients), three times per week
Trial: NCT00967044
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Starting dose of 5 mg every day by mouth with 1 cup (8 ounces) of water, in morning after eating a low-fat meal.
Trial: NCT01251029
Drug: N-acetylcysteine
RxNorm normalized name: N-acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1200 mg orally; 600mg i.v.
Trial: NCT01251029
Drug: Siran (N-acetylcysteine)
DrugBank: Asvasiran (DB05638)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005047
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00005047
Drug: vinblastine
RxNorm normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00232882
Drug: Candesartan Thiazide
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 16 mg for 4 weeks then added hydrochlorothiazide for 4 weeks
Trial: NCT04360044
Drug: Sham Cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 puffs of vaporized flower from which the THC and CBD have been extracted
Trial: NCT03290365
Drug: platelet rich plasma + Hyaluronic acid
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Platelet rich plasma (PRP) and Hyaluronic acid (HA) are beneficial for patients with osteoarthritis of knee.
Trial: NCT03290365
Drug: platelet rich plasma + normal saline
RxNorm normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The normal salin as the placebo intervention was injection control group.
Trial: NCT03961048
Drug: Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution bilaterally
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Variable initial post-operative dose of 10cc to 40cc bilaterally with a variable programmed dose to be repeated afterward of 10cc to 40cc of 0.2% ropivacaine every 6 hours bilaterally.
Trial: NCT03961048
Drug: Ropivacaine 0.2%-Sodium Chloride 0.9% Injectable Solution unilaterally
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Variable initial post-operative dose of 10cc to 40cc unilaterally with a variable programmed dose to be repeated afterward of 10cc to 40cc of 0.2% ropivacaine every 6 hours unilaterally.
Trial: NCT00667810
Drug: bapineuzumab
RxNorm normalized name: Bapineuzumab
DrugBank: Bapineuzumab (DB11715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
Trial: NCT00667810
Drug: bapineuzumab
RxNorm normalized name: Bapineuzumab
DrugBank: Bapineuzumab (DB11715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bapineuzumab 1.0 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
Trial: NCT00361335
Drug: Golimumab
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2mg/kg or 4mg/kg will be administered as an IV infusion over 30 minutes
Trial: NCT00232882
Drug: Atenolol Thiazide
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol 100 mg for 4 weeks followed by atenolol 100 mg + hydrochlorothiazide 12.5 mg for 4 weeks
Trial: NCT00232882
Drug: Thiazide Candesartan
DrugBank: Candesartan (DB13919)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide 25 mg for 4 weeks then added with Candesartan 16 mg
Trial: NCT00396591
Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4.0 mg/kg administered intravenously (IV) once every 2 weeks
Trial: NCT01267812
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given SC or IV
Trial: NCT01130636
Drug: Oseltamivir
RxNorm normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lactating women who present with clinical symptoms indicative of influenza will receive immediate treatment with oseltamivir (Tamiflu® 75 mg hard capsules) at a standard dose of 75 mg twice daily.
Trial: NCT01527136
Drug: entolimod
RxNorm normalized name: Entolimod
DrugBank: Entolimod (DB12304)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IM or SC
Trial: NCT02774096
Drug: xenon
RxNorm normalized name: xenon
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04609696
Drug: Danicopan: Powder-In-Capsule 1
DrugBank: Danicopan (DB15401)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danicopan (200 milligrams) will be administered orally on Day 1.
Trial: NCT03241342
Drug: GTx 024
RxNorm normalized name: toremifene
DrugBank: Toremifene (DB00539)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study drug is an opaque, white to off-white, size 5, oval Softgel capsule containing the active ingredient GTx-024.
Trial: NCT02234960
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab will be given according to summary of product characteristics as per clinical practice.
Trial: NCT00169819
Drug: Abciximab
RxNorm normalized name: Abciximab
DrugBank: Abciximab (DB00054)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03309007
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Total daily dose titrated up to 1500 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.
Trial: NCT04609696
Drug: Danicopan: Powder-In-Capsule 2
DrugBank: Danicopan (DB15401)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danicopan (200 milligrams) will be administered orally on Day 1.
Trial: NCT04609696
Drug: Danicopan: Tablet
DrugBank: Danicopan (DB15401)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danicopan (200 milligrams) will be administered orally on Day 1.
Trial: NCT00303953
Drug: belinostat
RxNorm normalized name: Belinostat
DrugBank: Belinostat (DB05015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01234792
Drug: 6 mg Experimental nicotine gum
RxNorm normalized name: nicotine Chewing Gum
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single 6 mg dose of an experimental nicotine gum, with a 36-hour washout between visits
Trial: NCT01234792
Drug: 4 mg Nicotine Gum/
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single 4 mg dose of Nicorette® gum, with a 36-hour washout between visits
Trial: NCT01234792
Drug: 2 mg Nicotine Gum
RxNorm normalized name: nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single 2 mg dose of Nicorette® gum, with a 36-hour washout between visits
Trial: NCT01295294
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg 3 times daily per oral during bleeding/spotting episodes
Trial: NCT01295294
Drug: Mirena (Levonorgestrel IUS, BAY86-5028)
RxNorm normalized name: levonorgestrel Intrauterine System [Mirena]
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: In vitro release rate 20 microgram/24 hours. Intrauterine system
Trial: NCT02668926
Drug: Lisdexamfetamine, d-amphetamine, Placebo
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
Trial: NCT02668926
Drug: d-amphetamine, Placebo, Lisdexamfetamine
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
Trial: NCT02668926
Drug: Placebo, Lisdexamfetamine, d-amphetamine
DrugBank: Amphetamine (DB00182)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
Trial: NCT03261960
Drug: Magnesium bowel preparation
RxNorm normalized name: cranberry preparation
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral bowel preparation
Trial: NCT03251963
Drug: Fixed Dose Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will be administered 40 mg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
Trial: NCT03251963
Drug: Variable Dose Enoxaparin
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible patients will be administered 0.5 mg/kg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
Trial: NCT00425334
Drug: Hemospan (MP4OX)
RxNorm normalized name: Aerospan
DrugBank: MP4 (DB05313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mL or 500 mL Hemospan (MP4OX)
Trial: NCT00173875
Drug: Iressa
RxNorm normalized name: Iressa
DrugBank: Gefitinib (DB00317)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02044796
Drug: Cladribine
RxNorm normalized name: Cladribine
DrugBank: Cladribine (DB00242)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02044796
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02044796
Drug: Mitoxantrone Hydrochloride
RxNorm normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01284296
Drug: Lidocaine digital block
RxNorm normalized name: Ivy Block
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One dose of lidocaine 2% injected locally into one finger (2 mls total)
Trial: NCT03055663
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)
Trial: NCT00124995
Drug: terbutaline
RxNorm normalized name: Terbutaline
DrugBank: Terbutaline (DB00871)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01216696
Drug: ipilimumab
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Eligible patients will receive 10 mg/kg ipilimumab every 3 weeks during a 10-week induction period, followed by a radiological assessment in week 12. Patients with clinical benefit will continue with an ipilimumab administration every 3 months starting at week 24 up to week 48 until the end of the study or until disease progression, toxicities requiring discontinuation , withdrawal of consent,pregnancy, death or lost to follow up whichever occurs first.
Trial: NCT01344174
Drug: 5 days dexamethasone therapy
RxNorm normalized name: dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: dexamethasone 10mg, intravenously, po daily for the first 5 days
Trial: NCT03939884
Drug: MuscleCare Topical Product
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Application of the product will be applied with six circular applications over the trigger point and left to rest for 7 minutes.
Trial: NCT03709823
Drug: Cytisine
RxNorm normalized name: Cytisine
DrugBank: Cytisine (DB09028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: film coated tablet containing 1.5 mg cytisine in a single tablet
Trial: NCT01194336
Drug: Huperzine A
RxNorm normalized name: Huperzine A
DrugBank: Huperzine A (DB04864)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dosage form: tablet dose frequency: once only
Trial: NCT01194336
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dosage form: tablet dosage frequency: once only
Trial: NCT01194336
Drug: Galantamine
RxNorm normalized name: Galantamine
DrugBank: Galantamine (DB00674)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: dosage form: tablet dosage frequency: once only
Trial: NCT02960919
Drug: parenteral ampicillin/ penicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00283790
Drug: zolpidem tartrate
RxNorm normalized name: Zolpidem Tartrate
DrugBank: Zolpidem (DB00425)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01466452
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single-dose aspirin in 100 mg 1 tablet every 24 hours
Trial: NCT01466452
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single-dose aspirin 200 mg 1 tablet every 24 hours
Trial: NCT01466452
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: double-dose aspirin 100 mg 1 tablet every 12 hours
Trial: NCT04163978
Drug: Budesonide
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Saline based sinus irrigation 1mg Budesinide solution
Trial: NCT01797601
Drug: Human Insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 160 U of insulin
Trial: NCT00380614
Drug: Lamivudine
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03732001
Drug: Anlotinib combined Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anlotinib ( 12mg, QD, PO d1-14, 21 days per cycle) and Docetaxel (60mg/m2, IV, d1, 21 days per cycle)
Trial: NCT03732001
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel (75mg/m2, IV, d1, 21 days per cycle)
Trial: NCT01269424
Drug: O6-benzylguanine
RxNorm normalized name: O6-benzylguanine
DrugBank: 6-O-benzylguanine (DB11919)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01269424
Drug: temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01361464
Drug: Tipifarnib
RxNorm normalized name: Tipifarnib
DrugBank: Tipifarnib (DB04960)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03326609
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perineural injection using a peripheral nerve block catheter and a constant infusion rate (10mL/h)
Trial: NCT00894049
Drug: reduced intensity conditionings
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: comparison of non myeloablative (Flu-TBI) and reduced intensity (FLU-BU-ATG)